Sign up to save your podcasts
Or
Share BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
View all episodes
By American Academy of Neurology
4.7
1919 ratings
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
More shows like Neurology Today in 5
View all
JAMA Editors' Summary
138 Listeners
NEJM This Week
323 Listeners
JAMA Clinical Reviews
498 Listeners
Neurology® Podcast
297 Listeners
Practical Neurology Podcast
46 Listeners
JAMA Neurology Author Interviews
13 Listeners
Annals On Call Podcast
191 Listeners
JAMA Medical News
95 Listeners
The Clinical Problem Solvers
515 Listeners
Neurology Minute
137 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
369 Listeners
Neurology Exam Prep Podcast
190 Listeners
The Curious Clinicians
375 Listeners
The Lancet Neurology in conversation with
6 Listeners
Continuum Audio
83 Listeners